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Abstract
Objective: To describe development and challenges of implementing a pharmacist-led chronic obstructive
pulmonary disease (COPD) clinic in the primary care setting.
Methods: Starting in October 2014, patients scoring 10-30 on the COPD Assessment Test (CAT) were
assigned to the intervention or control group. Intervention patients met with a pharmacist, who provided
medication and lifestyle counseling and therapy recommendations to the patients’ primary provider per
protocol. Control patients were encouraged to make an appointment with their primary provider for standard
care. Two months following the initial CAT administration, the survey was administered again to both study
groups by phone. The primary outcome was a comparison of change in CAT scores from baseline between the
groups. Secondary outcomes included an analysis of medications, smoking status, vaccination status, hospital
stays, visit attendance, and self-evaluation of disease progression.
Results: Of the 163 patients contacted, 29 were enrolled. Ninety-one percent of the patients screened with
the CAT were eligible based on the CAT requirement with an average baseline CAT score of 18.75. The
primary outcome, change in follow up CAT scores, were similar for intervention patients (n=18) versus
control patients (n=11), +0.8 versus +0.7 respectively. Four of the intervention patients attended their clinic
visit resulting in a 22% show rate.
Conclusion: Although our study was underpowered to detect between group differences, the elevated
baseline CAT scores support the need for therapy optimization in patients with COPD. Pharmacists are well
qualified to meet this need by providing medication counseling, smoking cessation, and therapy management.
Additional randomized controlled studies are needed to support improved outcomes for patients with COPD
when pharmacists are part of the clinical patient care team.
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Pharmacist intervention study, chronic obstructive pulmonary disease, COPD Assessment Test (CAT),
primary care
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Abstract 
Objective: To describe development and challenges of implementing a pharmacist-led chronic 
obstructive pulmonary disease (COPD) clinic in the primary care setting.  
Methods: Starting in October 2014, patients scoring 10-30 on the COPD Assessment Test (CAT) 
were assigned to the intervention or control group.  Intervention patients met with a pharmacist, who 
provided medication and lifestyle counseling and therapy recommendations to the patients’ primary 
provider per protocol.  Control patients were encouraged to make an appointment with their primary 
provider for standard care.  Two months following the initial CAT administration, the survey was 
administered ag in to both study groups by phone.  The primary outcome was a comparison of change 
in CAT scores from bas line between the groups.  Secondary outcomes included an analysis of 
medications, smoking status, vaccination status, hospital stays, visit attendance, and self-evaluation of 
disease progression.  
Results: Of the 163 patients contacted, 29 were enrolled.  Ninety-one percent of the patients screened 
with the CAT were eligible based on their CAT score with an average baseline score of 18.75.  The 
primary outcome, change in follow up CAT scores, were similar for intervention patients (n=18) 
versus control patients (n=11), +0.8 versus +0.7 respectively.  Four of the intervention patients 
attended their clinic visit resulting in a 22% show r te. 
Conclusion: Although our study was underpowered to detect between group differences, the elevated 
baseline CAT scores support the need for therapy optimization in patients with COPD.  Pharmacists 
are well qualified to meet this need by providing medication counseling, smoking cessation, and 
therapy management.  Additional randomized controlled studies are needed to support improved 
outcomes for patients with COPD when pharmacists are part of the clinical patient care team.  
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Introduction 
As the third leading cause of death in the United 
States, the economic burden of chronic obstructive 
pulmonary disease (COPD) is approximately $50 billion 
in direct and indirect healthcare costs.1 This cost is 
expected to increase as disease progression continues.1 
With hospital stays from COPD exacerbations accounting 
for the majority of this expense, optimal pharmacotherapy 
to limit exacerbations is vitally important.  Despite the 
high cost of COPD exacerbations, Make and colleagues’ 
retrospective analysis of over 50,000 patients with either 
commercial or Medicare insurance found that greater than 
66% of privately insured patients and over 70% of the 
Medicare population with COPD were not prescribed 
standard maintenance COPD pharmacotherapy.2  Their 
analysis found that the majority of patients were not 
receiving any COPD medications, and merely 5%-7% of 
patients were prescribed a short-acting β2-agonist, 
standard of care therapy for all individuals with COPD.3  
This study reveals that as many as 7 out of 10 patients 
with COPD may benefit from inhaler treatment 
optimization.   
The impact of pharmacist involvement in the 
management of COPD has been evaluated in several 
recent studies in community and health-systems 
settings.4,5,7-11  In a 2014 community-based study, 
significant reduction in the use of high-dose steroid 
therapy, an indicator of an acute exacerbation, was seen 
with pharmacist-led interventions in patients with asthma 
and COPD.4  This study involving over 109,000 patients 
demonstrated improvements related to inhaler technique, 
adherence to maintenance therapy, and cessation of 
suboptimal medications.   
Few studies have been conducted that evaluate 
pharmacist intervention in the primary care setting.  With 
direct access to general practitioners, the ambulatory care 
setting is especially conducive to the integration of 
clinical pharmacy services with standard practice.  One 
study in this setting did show improvement in COPD 
outcomes including hospitalization, adherence, and 
disease knowledge; however, the study was unable to 
detect a significant increase in health-related quality of 
life.5  A drawback of the study was the utilization of the 
St. George Respiratory Questionnaire (SGRQ), a 76-item 
tool used to assess symptoms, activity, and impact.6  
Although this tool is validated and designed for patients 
with COPD, it is cumbersome and not practical for use by 
healthcare providers on a routine basis.  A 2014 meta-
analysis focusing on the impact of pharmacist care for 
outpatients with COPD yielded similar results.  This 
review by Zhong and colleagues’ included 8 randomized 
controlled trials and supported positive pharmacist impact 
on medication adherence, hospital admission, and health-
related costs.7  
The aim of our study was to provide much 
needed data on the impact of clinical pharmacists in the 
primary care setting using methods that can feasibly be 
replicated in general practice.  The primary evaluation 
tool used in our study was the COPD Assessment Test 
(CAT).  This 8-question, validated test allows for scores 
from 0-40 with higher numbers indicating poorer COPD 
control.12 The questionnaire is designed to assess 
symptoms using a 1-5 scoring system that a patient could 
self-administer.  Patients scoring 10-30 on the CAT 
indicate that they are at a medium to high risk of a COPD 
exacerbation and were the target population for this study.  
A 2-point change in CAT score is considered a significant 
difference.13,14 The CAT user guide recommends for 
patients to be routinely screened with the test every 2 to 3 
months based on the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines.3 Positive 
trial results would support the expansion of clinical 
services offered by ambulatory care clinical pharmacists 
while strengthening collaboration with general 
practitioners to optimize patient care.  Challenges faced 
in this study were also examined to aid in the 
implementation and enhancement of future pharmacist-
directed, outpatient COPD management clinics.   
 
Methods 
 
This prospective pilot study was conducted 
within a private family physician practice with 2 separate 
clinical sites in West Tennessee.  Following institutional 
review board approval in September of 2014, the clinic’s 
information technology department created a patient call 
list for study recruitment.  The study inclusion criteria 
required patients to be at least 40 years of age, to have a 
current diagnosis of COPD based on active ICD-9 codes, 
and to score 10-30 on the COPD Assessment Test (CAT).  
Patients were excluded if they were unable to complete 
the CAT or provide informed consent, non-English 
speaking, or pregnant.  Patients were also excluded if their 
CAT score was less than 10, indicating a low exacerbation 
risk, or greater than 30, indicating very high risk.13 
Patients scoring greater than 30 were encouraged to meet 
with their primary care physician (PCP) for referral to a 
pulmonary specialist.  Nine of the PCPs within the 
practice signed the study protocol, allowing their patients 
to be enrolled in the study.   
The patient call list contained the names and 
phone numbers of clinic patients who met the age and 
diagnosis requirements of the study and had visited their 
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participating PCP in the last 2 years.  These patients were 
initially administered the CAT by phone from October 
through November of 2014.  A standardized patient phone 
script was used to recruit patients.  Study enrollees were 
originally assigned in a 1:1 ratio to either the intervention 
group or control group.  The intervention group patients 
were scheduled to meet with the pharmacy resident for a 
face-to-face visit at their PCP’s clinic location.  The 
control group was encouraged to make an appointment 
with their PCP for standard care.  Due to the low clinic 
visit show rate in the intervention group, patients were 
assigned to the intervention group at an increased ratio in 
the latter half of study recruitment.  In both groups, a 
follow up CAT was to be administered 2 months from the 
initial CAT. 
The intervention visit with the pharmacist 
followed a standardized protocol that included a COPD 
staging assessment based on the GOLD guidelines.3 The 
visit included a review of relevant medical history, inhaler 
technique evaluation, smoking cessation counseling, 
exercise coaching, and immunization recommendations 
as needed.  Pharmacist recommendations to optimize 
COPD inhaler therapy were discussed with the PCP prior 
to initiation and followed a standardized protocol.  
Patients were also provided with an individualized goal 
sheet and visit summary. 
The primary outcome of our study was an 
intention-to-treat comparison of changes in CAT scores 
from baseline between the intervention and standard care 
groups.  Secondary outcomes include an analysis of 
COPD medications, smoking status, vaccination status, 
hospital stays, clinic visit attendance, and self-evaluation 
of disease progression.   
 
Results 
 
Twenty-nine patients were enrolled in the study 
with 18 and 11 patients assigned to the intervention group 
and control group respectively (Figure 1).  Forty-six 
percent (n=30) of the patients who were successfully 
contacted by phone denied a diagnosis of COPD.  These 
patients confirmed lack of current inhaler use or 
breathing-related health problems.  Of the remaining 104 
patients called, the majority either had wrong numbers 
recorded in the clinic’s database or were unable to be 
reached by phone.  Three patients were no longer patients 
of the participating providers.  Three patients did not 
qualify based on their CAT scores of 5, 6, and 31 
respectively.  The patient with a score greater than 30 was 
referred to the PCP for evaluation and potential follow up 
with a pulmonary specialist per the study protocol.  
Four of the eighteen patients in the intervention 
group attended their scheduled pharmacist clinic visit, 
resulting in a show rate of 22%.  Fifty-seven percent of 
the control group attended an appointment with their PCP 
in between the initial and follow up CAT.  The follow up 
CAT was completed in 89% (n=16) and 64% (n=7) of the 
intervention and control group subjects respectively.   
 
Figure 1. Study Population Recruitment and 
Progression  
 
aPatients were unable to be reached by phone due to either inaccurate 
phone numbers or not answering the phone. 
bOf the 6 ineligible patients, 3 patients had changed primary care 
providers, and 3 patients were excluded due to CAT scores of 5, 6, 
and 31. 
The average initial CAT score in the intervention 
group was 20.6 and 16.9 in the control group (Table 1).  
The 2-month follow up CAT score was 21.4 and 17.6 in 
the intervention and control groups respectively.  The 
primary outcome, difference in CAT scores from 
baseline, was an increase of 0.8 in the intervention group 
versus an increase of 0.7 in the control group.  
Information collected on secondary outcomes is included 
in Table 2.  Three of the intervention group patients 
reported that they felt their COPD symptoms had 
improved two months from the initial CAT versus zero 
163  Patients Called
60% Unable to 
Reacha (n=98)
40% Reached 
Successfully (n=65)
18% Denied COPD
(n=30)
18% Enrolled
(n=29)
Intervention Group
(n=18)
22% Attended Clinic 
Visit (n=4)
Follow Up 
Completed
89% (n=16)
Control Group
(n=11)
57% Attended PCP 
Visit (n=4)
Follow Up 
Completed
64% (n=7)
4% Ineligibleb
(n=6) 
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patients in the control group.  The intervention group was 
comprised of 50% active tobacco users versus 9% in the 
control group. 
bSD = standard deviation 
aCAT = Chronic Obstructive Pulmonary Disease Assessment Test 
 
Table 2.  Comparison of Secondary Data Collection 
Outcome Intervention 
Group (%) 
N=18 
Control 
Group (%) 
N=11 
Perceived Change in 
COPD Control 
Worsened 
Improved 
Same 
 
 
4 (22) 
3 (17) 
11 (61) 
 
 
3 (27) 
0 (0) 
8 (73) 
Tobacco Cessation 
During Study 
1 (6) 0 (0) 
Medication Change 4 (22)a 2 (18)b 
Vaccinations Received  1 (6) 0 (0) 
Hospital Stays 1 (6) 1 (9) 
aPercentages based on intent-to-treat analysis out of the total number 
of patients enrolled.  Patients lost to follow up assessment were 
included in percent calculations with no change in secondary items. 
bMedication changes include initiation of 2 albuterol inhalers and 1 
tiotropium inhaler 
cMedication change included initiation of an ipratropium/albuterol 
combination inhaler and one steroid dose pack 
 
Discussion 
 
There were several challenges and limitations 
identified during this study.  The primary limitation was 
our inability to run statistics due to the small sample size.  
A decrease in the 2-month CAT score of at least 2 points 
from baseline would have supported the benefit of 
pharmacist intervention from standard care.  In our study, 
the 2-month CAT scores for both groups increased 
slightly.  Although the significance of this less than 1-
point increase cannot be determined, we have identified 
several potential contributing factors. Firstly, baseline 
characteristics were dramatically different between 
groups.  For example, 50% of the intervention group 
reported to be active smokers compared to 9% in the 
control group.  Also, the average initial CAT score in the 
intervention group was 3.7 points higher than in the 
control group.  Secondly, the subjective nature of the CAT 
may have led to non-COPD related changes in CAT 
scores. While these outliers may not impact the integrity 
of overall CAT scores for a large study population, our 
small cohort was especially vulnerable to potential 
confounders. For example, 2 of the intervention patients 
reported factors such as a heart failure exacerbation and 
family stress as the causes for the worsening of their 
COPD symptoms.  Lastly, the CAT score did not 
consistently reflect our patients’ perceived change in 
COPD control.   Although 2-month follow up CAT scores 
did not improve, 3 of the intervention group patients 
reported improvement in the COPD control while no 
patients reported improvement in the control group.  
Perceived COPD control and quality of life are areas for 
future research.   
The main contributor to our limited study size 
was slow patient enrollment.  Patient screening was based 
on ICD-9 codes to eliminate the initial time lag associated 
with reliance on provider referral.  Although this approach 
allowed the pharmacist to recruit patients immediately 
upon study approval, it resulted in a time-consuming 
recruitment process.  Only 40% of the patients called were 
successfully reached by phone.  Of those patients 
successfully reached, about half denied a diagnosis of 
COPD.  Patients who denied having COPD confirmed 
that they currently had no difficulty breathing and were 
not using any type of inhaler therapy.  This discrepancy 
in confirmed diagnosis of COPD and ICD-9 codes was 
consistent with that seen in a study by Cooke and 
colleagues.15 As a solution to reduce this administration 
error, Cooke’s analysis supports using a combination 
approach such as ICD-9 codes and chart documentation 
of COPD medication prescriptions.  A limitation of this 
method is that it excludes patients with COPD who are 
not currently prescribed COPD medications but who may 
benefit from therapy initiation.  A similar limitation 
would be faced with requiring pulmonary function tests.  
While greater reliance would be placed on provider 
support, physician referral to a pharmacist-led COPD 
clinic would bypass these challenges.   
In addition to slow recruitment, clinic visit 
attendance was low in both study arms.  As seen in figure 
1, 4 patients in each study group attended a clinic visit 
during the study.  Although reasons for clinic no-shows 
varied, lack of transportation was reported to be a 
common barrier to visit attendance.  Clinic room space 
and availability limited flexibility for scheduling 
appointments as well.  Neither of the clinic sites were the 
pharmacists’ main practice sites, limiting flexibility for 
rescheduling or impromptu appointments.  The low show 
Table 1. Comparison of CATa Scores 
Average CAT 
Scores 
Intervention Group 
(SDb) 
Control Group 
(SD) 
Initial 20.6 (4.3) 16.9 (4.3) 
2-Month Follow 
Up 
21.6 (6.0) 17.6 (4.9) 
Difference  +0.8 (5.5) +0.7 (2.3) 
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rate could also indicate low health literacy or inaccurate 
beliefs regarding disease state severity and the possibility 
of improved symptoms control.  In a cohort by Kale and 
colleagues, low health literacy was associated with illness 
beliefs that were determinants for decreased adherence to 
self-management and COPD medications.16 These issues 
again may potentially be mitigated by physician referral 
to the COPD management service along with scheduling 
these pharmacist visits in conjunction with provider visits 
to reduce travel burden.  
The high cost of inhaler therapy was an additional 
barrier identified in our patient population.  Patients were 
reluctant to initiate and adhere to expensive medication 
therapy.  Providers were sometimes hesitant to prescribe 
these high cost COPD treatments, especially in patients 
with concomitant health issues and many additional 
medications.  The pharmacist’s role in navigating patients 
through the medication assistance process and consequent 
impact on patient adherence and provider outlook is a 
potential avenue for future research.    
Lastly, primary care provider support was a key 
factor in our study.  As with all new services, the benefit 
of the service needs to be effectively communicated to 
both the patients and their providers.  In our experience, 
the vast majority of providers welcomed pharmacist 
involvement in spending focused time with their patients 
to optimize COPD therapy.  For future study, utilization 
of provider support of this service could potentially 
improve the patient recruitment processes as well as visit 
attendance.  
    
Conclusion 
 
The study’s sample size was underpowered to 
apply a statistical analysis for primary and secondary 
endpoints.  However, the study did strongly support the 
need for optimization of COPD therapy in our patient 
population with CAT scores in 9 out of 10 patients 
indicating a medium to high risk of a COPD exacerbation.  
Our study identified that despite an initial lag time, 
recruitment by provider referral could provide several 
benefits.  Provider referral could potentially reduce 
recruitment time, labor, and administrative screening 
error while increasing patients’ perceived value of the 
service.  In addition, coupling pharmacist-led, COPD 
clinic visits with provider appointments could be an 
effective method to improve patient show rate.  Areas for 
future COPD study include maximizing provider support, 
evaluating the pharmacist’s role in the medication 
assistance process, and assessing patient beliefs regarding 
disease state severity and the possibility of improved 
symptoms control.   
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